SCHEMBL3205915

SCHEMBL3205915

C=CCOc1ccc2c(ccn2S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 0.65
POLB P06746 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
HDAC1 Q13547 5/20 0.54
HDAC6 Q9UBN7 4/20 0.54
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.52
TSHR P16473 1/20 0.52
HTT P42858 1/20 0.52
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27615542 0.84 HTR6 (0.55) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL707042 0.82 HDAC1 (0.74) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL1996167 0.81 HTR6 (0.67) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL430473 0.79 HTR6 (1.00) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL25455094 0.79 HTR6 (0.66) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL1997952 0.75 HTR6 (0.61) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL31159329 0.74 HDAC1 (0.66) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL6339394 0.74 HTR6 (0.56) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL1993693 0.73 HTR6 (0.57) HTR6POLBL3MBTL1HDAC1HDAC6
SCHEMBL6851383 0.72 MEN1 (0.68) HTR6POLBL3MBTL1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674818-B2 Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH LLC (US) 2010-03-09 US disclosed
EP-1569901-B1 ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH CORP (US) 2008-10-15 EP disclosed
US-20070259922-A1 Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2007-11-08 US disclosed
US-7259182-B2 Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders WYETH (US) 2007-08-21 US disclosed
CN-1723198-A Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH CORP (US) 2006-01-18 CN disclosed
US-20040138283-A1 Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138283-A1 Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) SERPINE1, PLAT, SERPINC1 HTR6 500/4885POLB 2931/4885L3MBTL1 1951/4885
US-20070259922-A1 Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) SERPINE1, SERPINC1, PLAT HTR6 602/4885POLB 3237/4885L3MBTL1 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.